Drugs / Desonide
Desonide
also known as
D-2083 · Desonate · Desonida · Desonide component of tridesilon · Desowen · NSC-759226 · Tridesilon · Verdeso
Small molecule targets NR3C1 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DESONIDE | — | 1972-01-04 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03437005 | Jan 2013 → Sep 2026 overdue | — | University of California, Davis | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00690833 | Aug → Dec 2007 | atopic eczema | Wake Forest University | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT03758365 Comparator | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03386032 Comparator | Nov 2017 → Aug 2018 | atopic eczema | Procter and Gamble | Completed | Mixed |
| Phase 3 | NCT02286700 Comparator | Nov 2014 → Feb 2015 | atopic eczema | NeoStrata Company, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT01467362 Background | Nov 2011 → May 2012 | atopic eczema | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT02732314 Comparator | Mar → Jun 2016 | atopic eczema | Procter & Gamble Beauty | Completed | No outcome recorded |
| Phase 4 | NCT02624544 Comparator | Jan 2016 | psoriasis | EMS | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01542138 Comparator | Jul 2011 → Nov 2012 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 4 | NCT00828412 Comparator | Mar → Aug 2009 | atopic eczema | Promius Pharma, LLC | Completed | No outcome recorded |
| — | NCT07295678 Comparator | Jan → Jul 2026 overdue | atopic eczema | CEN Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | desonide | “desonide 0.1%, or betamethasone 0.05% in case treatment escalation is required.” NCT07295678 ↗ |
| Known as | D-2083 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Desonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Desonida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Desonide component of tridesilon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Desowen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | NSC-759226 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Tridesilon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Known as | Verdeso | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201109 ↗ |
| Action | Activate | “Glucocorticoid receptor agonist” CHEMBL1201109 ↗ |
| Modality | Small molecule | — CHEMBL1201109 ↗ |
| Route | Topical | “topical desonide hydrogel 0.05%” NCT00690833 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor agonist” CHEMBL1201109 ↗ |